GoodRx Holdings, Inc.
NASDAQ:GDRXMedical - Healthcare Information Services
+$0.05 today
- Market cap
- $1.15B
- Beta
- 1.61
- P/E (TTM)
- 44.0
- EPS (TTM)
- $0.06
Volume 0.66M
Average 1.61M
GDRX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
GoodRx Holdings, Inc.NASDAQ: GDRX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $16.51M fell 13.9% year over year, ahead of the -39.9% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at -13.9% a year.
Context
- Stock-based compensation amounted to 9.6% of revenue in FY2025, down 2.9 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -13.9% holds above the trailing-twelve-month pace of -39.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 76.63M USD
- Year-over-year change
- -22.6%
- 4-year CAGR
- -16.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 76.63M | -22.6% |
| FY2024 | 2024-12-31 | 99.03M | -5.5% |
| FY2023 | 2023-12-31 | 104.82M | -12.8% |
| FY2022 | 2022-12-31 | 120.23M | -25.1% |
| FY2021 | 2021-12-31 | 160.46M | — |
Stock-Based Compensation vs competitors
How GDRX compares with its peers on the latest reported figures
- GDRX's LTM Mar 2026 stock-based compensation of $55.99M is the 2nd largest of the 4 companies compared; the peer median is $16.98M.
- Its year-over-year change of -39.9% is the 2nd highest of 4, against a peer median of -45.8%.
- Stock-based compensation amounts to 7.1% of revenue for GDRX, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $69.86M | -45.8% | -28.3% | 2.8% | |
| LTM Mar 2026 | $55.99M | -39.9% | -13.9% | 7.1% | |
| LTM Mar 2026 | $16.98M | -56.1% | -31.2% | 7.2% | |
| LTM Mar 2026 | $7.95M | -35.1% | -8.6% | 3.6% | |
| Peer median (excluding GDRX) | $16.98M | -45.8% | -28.3% | 3.6% | |
Competitors are the stored peer set for GDRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.25M) | (32.83M) | (8.87M) | 16.39M | 30.44M |
| Depreciation & Amortization | 34.54M | 54.18M | 111.77M | 69.54M | 85.22M |
| Deferred Income Tax | 12.85M | (497K) | (65.56M) | (11.91M) | 20.07M |
| Stock-Based Compensation | 160.46M | 120.23M | 104.82M | 99.03M | 76.63M |
| Change in Working Capital | (11.8M) | (20.29M) | (21.94M) | 2.09M | (56.44M) |
| Accounts Receivables | (43.95M) | 1.38M | (26.47M) | (2.33M) | (88.02M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 4.21M | (874K) | 17.46M | (21.24M) | 4.1M |
| Other Working Capital | 27.95M | (20.79M) | (12.93M) | 25.66M | 27.47M |
| Other Non-Cash Items | 7.98M | 25.98M | 18.07M | 8.76M | 11.99M |
| Operating Cash Flow | 178.78M | 146.78M | 138.29M | 183.89M | 167.9M |
| Capital Expenditures | (34.46M) | (55.21M) | (55.77M) | (70.35M) | (3.52M) |
| Acquisitions (Net) | (144.28M) | (155.28M) | 0 | 0 | (30M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (29.89M) | (51.25M) | (54.72M) | (70.35M) | (87.68M) |
| Investing Cash Flow | (178.73M) | (210.5M) | (55.77M) | (70.35M) | (119.96M) |
| Debt Repayment | (7.03M) | (7.03M) | (5.27M) | (167.01M) | (3.75M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (101.72M) | (103.97M) | (158.85M) | (206.94M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (23.5M) | (11.48M) | (58.15M) | (11.65M) | (23.78M) |
| Financing Cash Flow | (30.53M) | (120.23M) | (167.4M) | (337.5M) | (234.47M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (30.48M) | (183.94M) | (84.87M) | (223.95M) | (186.53M) |
| Free Cash Flow | 144.32M | 91.57M | 82.53M | 113.55M | 164.38M |
GoodRx Holdings, Inc.
NASDAQ:GDRX
Intrinsic Alpha fair value
Locked
Current Price
$3.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.